Lilly Signs US$1.9 B Global Collaboration with Repertoire for Autoimmune Diseases

By Hitesh Udar

Pharma Deals Review: Vol 2026 Issue 2 (Table of Contents)

Published: 12 Feb-2026

DOI: 10.3833/pdr.v2026.i2.2997     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

Lilly has entered into a global licensing and collaboration agreement with Repertoire Immune Medicines, securing exclusive rights to advance Repertoire’s early‑stage discoveries into novel tolerising therapies targeting multiple autoimmune diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details